Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Dyslipidemia

  Free Subscription


04.12.2017

2 Am J Cardiol
6 Atherosclerosis
1 Circulation
6 Curr Opin Lipidol
3 Int J Cardiol
2 J Clin Psychiatry
2 N Engl J Med
1 PLoS Genet
4 PLoS One
2 Postgrad Med


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Cardiol

  1. TADA H, Kawashiri MA, Okada H, Nakahashi T, et al
    Assessments of Carotid Artery Plaque Burden in Patients With Familial Hypercholesterolemia.
    Am J Cardiol. 2017 Aug 30. pii: S0002-9149(17)31382.
    PubMed     Text format     Abstract available

  2. GOYAL A, Gupta T, Aronow WS, Panza JA, et al
    Making the Case for Universal Treatment of Hypercholesterolemia.
    Am J Cardiol. 2016 May 5. pii: S0002-9149(16)30549.
    PubMed     Text format    


    Atherosclerosis

  3. RALLIDIS LS, Triantafyllis AS, Tsirebolos G, Katsaras D, et al
    Prevalence of heterozygous familial hypercholesterolaemia and its impact on long-term prognosis in patients with very early ST-segment elevation myocardial infarction in the era of statins.
    Atherosclerosis. 2016;249:17-21.
    PubMed     Text format     Abstract available

  4. MICKIEWICZ A, Chmara M, Futema M, Fijalkowski M, et al
    Efficacy of clinical diagnostic criteria for familial hypercholesterolemia genetic testing in Poland.
    Atherosclerosis. 2016;249:52-58.
    PubMed     Text format     Abstract available

  5. ARAI H, Teramoto T, Daida H, Ikewaki K, et al
    Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2016 Mar 25. pii: S0021-9150(16)30092.
    PubMed     Text format     Abstract available

  6. XIANG R, Fan LL, Lin MJ, Li JJ, et al
    The genetic spectrum of familial hypercholesterolemia in the central south region of China.
    Atherosclerosis. 2017;258:84-88.
    PubMed     Text format     Abstract available

  7. WALDMANN E, Vogt A, Crispin A, Altenhofer J, et al
    Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study).
    Atherosclerosis. 2017;259:20-25.
    PubMed     Text format     Abstract available

  8. HIGUCHI S, Kabeya Y, Kato K
    Visceral-to-subcutaneous fat ratio is independently related to small and large cerebrovascular lesions even in healthy subjects.
    Atherosclerosis. 2017;259:41-45.
    PubMed     Text format     Abstract available


    Circulation

  9. VALLEJO-VAZ AJ, Robertson M, Catapano AL, Watts GF, et al
    LDL-Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men with Primary Elevations of LDL-Cholesterol Levels of 190 mg/dL or Above: Analyses from the WOSCOPS 5-year Randomised Trial and 20-year Observational Follow-Up.
    Circulation. 2017 Sep 6. pii: CIRCULATIONAHA.117.027966.
    PubMed     Text format     Abstract available


    Curr Opin Lipidol

  10. MUNDAL L, Retterstol K
    A systematic review of current studies in patients with familial hypercholesterolemia by use of national familial hypercholesterolemia registries.
    Curr Opin Lipidol. 2016.
    PubMed     Text format     Abstract available

  11. BOGSRUD MP, Ulven SM, Holven KB
    Does intrauterine exposure to hypercholesterolemia adversely affect familial hypercholesterolemia phenotype?
    Curr Opin Lipidol. 2016.
    PubMed     Text format     Abstract available

  12. GENCER B, Nanchen D
    Identifying familial hypercholesterolemia in acute coronary syndrome.
    Curr Opin Lipidol. 2016.
    PubMed     Text format     Abstract available

  13. HARALAMBOS K, Ashfield-Watt P, McDowell IF
    Diagnostic scoring for familial hypercholesterolaemia in practice.
    Curr Opin Lipidol. 2016;27:367-374.
    PubMed     Text format     Abstract available

  14. BJORNSON E, Adiels M, Taskinen MR, Boren J, et al
    Kinetics of plasma triglycerides in abdominal obesity.
    Curr Opin Lipidol. 2017;28:11-18.
    PubMed     Text format     Abstract available

  15. TAHER J, Farr S, Adeli K
    Central nervous system regulation of hepatic lipid and lipoprotein metabolism.
    Curr Opin Lipidol. 2017;28:32-38.
    PubMed     Text format     Abstract available


    Int J Cardiol

  16. KISHIMOTO S, Kajikawa M, Maruhashi T, Iwamoto Y, et al
    Endothelial dysfunction and abnormal vascular structure are simultaneously present in patients with heart failure with preserved ejection fraction.
    Int J Cardiol. 2017 Jan 5. pii: S0167-5273(16)32405.
    PubMed     Text format     Abstract available

  17. DUFOUR R, Bergeron J, Gaudet D, Weiss R, et al
    Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment.
    Int J Cardiol. 2017;228:754-760.
    PubMed     Text format     Abstract available

  18. KUWABARA M, Niwa K, Nishihara S, Nishi Y, et al
    Hyperuricemia is an independent competing risk factor for atrial fibrillation.
    Int J Cardiol. 2016 Nov 15. pii: S0167-5273(16)32841.
    PubMed     Text format     Abstract available


    J Clin Psychiatry

  19. BRUINS J, Pijnenborg GHM, van den Heuvel ER, Visser E, et al
    Persistent Low Rates of Treatment of Metabolic Risk Factors in People With Psychotic Disorders: A PHAMOUS Study.
    J Clin Psychiatry. 2017;78:1117-1125.
    PubMed     Text format     Abstract available

  20. JENSEN KG, Correll CU, Ruda D, Klauber DG, et al
    Pretreatment Cardiometabolic Status in Youth With Early-Onset Psychosis: Baseline Results From the TEA Trial.
    J Clin Psychiatry. 2017 Jan 17. doi: 10.4088/JCP.15m10479.
    PubMed     Text format     Abstract available


    N Engl J Med

  21. GIUGLIANO RP, Sabatine MS, Ott BR
    Cognitive Function in a Randomized Trial of Evolocumab.
    N Engl J Med. 2017;377:1997.
    PubMed     Text format    

  22. CALABRO P, Gragnano F, Pirro M
    Cognitive Function in a Randomized Trial of Evolocumab.
    N Engl J Med. 2017;377:1996-7.
    PubMed     Text format    


    PLoS Genet

  23. DAVIS JP, Huyghe JR, Locke AE, Jackson AU, et al
    Common, low-frequency, and rare genetic variants associated with lipoprotein subclasses and triglyceride measures in Finnish men from the METSIM study.
    PLoS Genet. 2017;13:e1007079.
    PubMed     Text format     Abstract available


    PLoS One

  24. CHHOUN P, Tuot S, Harries AD, Kyaw NTT, et al
    High prevalence of non-communicable diseases and associated risk factors amongst adults living with HIV in Cambodia.
    PLoS One. 2017;12:e0187591.
    PubMed     Text format     Abstract available

  25. AUCKLE R, Su B, Li H, Xu S, et al
    Familial hypercholesterolemia in Chinese patients with premature ST-segment-elevation myocardial infarction: Prevalence, lipid management and 1-year follow-up.
    PLoS One. 2017;12:e0186815.
    PubMed     Text format     Abstract available

  26. SORENSEN BM, Houben AJHM, Berendschot TTJM, Schouten JSAG, et al
    Cardiovascular risk factors as determinants of retinal and skin microvascular function: The Maastricht Study.
    PLoS One. 2017;12:e0187324.
    PubMed     Text format     Abstract available

  27. REIGER S, Jardim TV, Abrahams-Gessel S, Crowther NJ, et al
    Awareness, treatment, and control of dyslipidemia in rural South Africa: The HAALSI (Health and Aging in Africa: A Longitudinal Study of an INDEPTH Community in South Africa) study.
    PLoS One. 2017;12:e0187347.
    PubMed     Text format     Abstract available


    Postgrad Med

  28. NELSON JR, True WS, Le V, Mason RP, et al
    Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?
    Postgrad Med. 2017;129:822-827.
    PubMed     Text format     Abstract available

  29. WOJCIK C
    Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
    Postgrad Med. 2017;129:801-810.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Dyslipidemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: